Patents by Inventor Mariusz Z. Ratajczak
Mariusz Z. Ratajczak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11312940Abstract: Provided are methods for isolating subpopulations of stem cells. In some embodiments, the presently disclosed methods include selecting subsets of cells that are positive for CD34 or Sca-1, are further positive for one or more of FSHR, LHCGR, PRLR, AR, ESR?, ESR?, and PGR; and are negative for each of CD45R/B220, Gr-1, TCR??, TCR??, CD11b, and Ter-119. In some embodiments, the subpopulations are further fractioning into CD45? and CD45+ fractions. Also provided are populations of stem cells isolated by the presently disclosed methods, compositions that include the presently disclosed subpopulations in pharmaceutically acceptable carriers, methods for expanding stem cells, methods for stimulating proliferation of MSCs, methods for treating subjects suffering from exposure to radiation, and methods for producing gametes in vitro.Type: GrantFiled: August 31, 2016Date of Patent: April 26, 2022Assignee: University of Louisville Research Foundation, Inc.Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia
-
Publication number: 20220056404Abstract: Methods for ex vivo expansion of very small embryonic like stem cells in the absence of feeder cells are provided. In some embodiments the methods include providing a plurality of VSELs; and growing the VSELs in a culture medium that includes a histone deacetylase inhibitor, luteinizing hormone, follicle-stimulating hormone, and optionally transforming growth factor beta in an amount that is sufficient to overcome quiescence of the VSELs. Also provided are feeder cell-free cell cultures, ex vivo expanded VSELs, pharmaceutical compositions that include the disclosed ex vivo expanded VSELs, methods for overcoming quiescence in VSELs, methods for re-establishing imprinting in VSELs, method for treating injuries to tissues in subjects, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for treating radiation exposure in subjects, and methods that relate to regenerative medicine.Type: ApplicationFiled: July 26, 2021Publication date: February 24, 2022Applicant: University of Louisville Research Foundation, Inc.Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia, Donald Miller
-
Patent number: 11072777Abstract: Methods for ex vivo expansion of very small embryonic like stem cells in the absence of feeder cells are provided. In some embodiments the methods include providing a plurality of VSELs; and growing the VSELs in a culture medium that includes a histone deacetylase inhibitor, luteinizing hormone, follicle-stimulating hormone, and optionally transforming growth factor beta in an amount that is sufficient to overcome quiescence of the VSELs. Also provided are feeder cell-free cell cultures, ex vivo expanded VSELs, pharmaceutical compositions that include the disclosed ex vivo expanded VSELs, methods for overcoming quiescence in VSELs, methods for re-establishing imprinting in VSELs, method for treating injuries to tissues in subjects, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for treating radiation exposure in subjects, and methods that relate to regenerative medicine.Type: GrantFiled: March 3, 2017Date of Patent: July 27, 2021Assignee: University of Louisville Research Foundation, Inc.Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia, Donald Miller
-
Publication number: 20190093075Abstract: Methods for ex vivo expansion of very small embryonic like stem cells in the absence of feeder cells are provided. In some embodiments the methods include providing a plurality of VSELs; and growing the VSELs in a culture medium that includes a histone deacetylase inhibitor, luteinizing hormone, follicle-stimulating hormone, and optionally transforming growth factor beta in an amount that is sufficient to overcome quiescence of the VSELs. Also provided are feeder cell-free cell cultures, ex vivo expanded VSELs, pharmaceutical compositions that include the disclosed ex vivo expanded VSELs, methods for overcoming quiescence in VSELs, methods for re-establishing imprinting in VSELs, method for treating injuries to tissues in subjects, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for treating radiation exposure in subjects, and methods that relate to regenerative medicine.Type: ApplicationFiled: March 3, 2017Publication date: March 28, 2019Applicant: University of Louisville Research Foundation, Inc.Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia, Donald Miller
-
Publication number: 20170108499Abstract: Provided are methods for isolating subpopulations of stem cells. In some embodiments, the presently disclosed methods include selecting subsets of cells that are positive for CD34 or Sca-1, are further positive for one or more of FSHR, LHCGR, PRLR, AR, ESR?, ESR?, and PGR; and are negative for each of CD45R/B220, Gr-1, TCR??, TCR??, CD11b, and Ter-119. In some embodiments, the subpopulations are further fractioning into CD45? and CD45+ fractions. Also provided are populations of stem cells isolated by the presently disclosed methods, compositions that include the presently disclosed subpopulations in pharmaceutically acceptable carriers, methods for expanding stem cells, methods for stimulating proliferation of MSCs, methods for treating subjects suffering from exposure to radiation, and methods for producing gametes in vitro.Type: ApplicationFiled: August 31, 2016Publication date: April 20, 2017Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia
-
Publication number: 20160151421Abstract: Methods for isolating a CD133+/CD45neg/GlyAneg subpopulation of umbilical cord blood cells are disclosed. In some embodiments, the methods include providing an initial population of umbilical cord blood cells; contacting the initial population of cells with a first antibody that is specific for CD133, a second antibody that is specific for CD45, and a third antibody that is specific for Glycophorin A (GlyA) under conditions sufficient to allow binding of each antibody to its target, if present, on each cell of the initial population of cells; and isolating a subpopulation of cells that are CD133+, CD45neg, and GlyAneg. Also provided are isolated populations of CD133+/GlyAneg/CD45neg stem cells isolated from cord blood, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for inducing hematopoietic competency in CD133+/GlyAneg/CD45neg stem cells, and cell culture systems that include CD133+/GlyAneg/CD45neg stem cells.Type: ApplicationFiled: December 3, 2015Publication date: June 2, 2016Inventors: Janina Ratajczak, Ewa K. Zuba-Surma, Mariusz Z. Ratajczak
-
Patent number: 9233127Abstract: The present invention provides for enhancing engraftment by co-infusing at least two partially HLA matched umbilical cord blood (“UCB”) units. The invention further provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention further provides for enhancing the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway and that C3a and LL-37 are useful for this method. It is also disclosed herein that fragments of C3a (e.g., des-Arg) are effective in the methods of the invention, including enhancing homing of HSPCs to BM. The invention further encompasses the disclosure herein of NFAT1 regulation post-transcriptionally by both mir-184 and IFN-?. The present invention further provides for measuring and using differences between UCB and adult CD4+/45RA+ T-cells as a means of defining strategies to enhance optimal allogeneic stem cell transplantation outcomes.Type: GrantFiled: February 27, 2013Date of Patent: January 12, 2016Assignee: University of Virginia Patent FoundationInventors: Mary J. Laughlin, Mariusz Z. Ratajczak, Claudio Brunstein
-
Publication number: 20150174173Abstract: The invention provides adult pluripotent stem cells (PSC) for treatment or prophylaxis for radiological exposure. In an embodiment of the invention, the cells are very small embryonic like stem cells (VSELs). The VSELs can be used to rescue the hematopoietic and immune systems of individuals suffering from the delayed effects of acute radiation syndrome (ARS).Type: ApplicationFiled: June 24, 2013Publication date: June 25, 2015Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia, Denis Rodgerson
-
Publication number: 20140154219Abstract: Methods for purifying very small embryonic-like (VSEL) stem cells from populations of cells suspected of including VSEL stem cells are provided. In some embodiments, the methods include (a) providing a population of cells suspected of including a VSEL stem cell; and (b) isolating a CD45neg/GlyAneg/CD133+/ALDHhigh subpopulation, a CD45neg/GiyAneg/CD133+/ALDlow subpopulation, a CD45neg/Linneg/SSEA-4+/ALDHhigh subpopulation, a CD45neg/Linneg/SSEA-4/AiOlow subpopulation, or any combination thereof from the population, whereby a VSEL stem cell is purified from the population. Also provided are methods for generating in vitro hematopoietic colonies derived from VSEL stem cells and methods for generating lympho-hematopoietic chimerism in a subject.Type: ApplicationFiled: April 2, 2012Publication date: June 5, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Janina Ratajczak, Mariusz Z. Ratajczak
-
Publication number: 20140106446Abstract: Methods for isolating a CD133+/CD45neg/GlyAneg subpopulation of umbilical cord blood cells are disclosed. In some embodiments, the methods include providing an initial population of umbilical cord blood cells; contacting the initial population of cells with a first antibody that is specific for CD133, a second antibody that is specific for CD45, and a third antibody that is specific for Glycophorin A (GlyA) under conditions sufficient to allow binding of each antibody to its target, if present, on each cell of the initial population of cells; and isolating a subpopulation of cells that are CD133+, CD45neg, and GlyAneg. Also provided are isolated populations of CD133+/GlyAneg/CD45neg stem cells isolated from cord blood, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for inducing hematopoietic competency in CD133+/GlyAneg/CD45neg stem cells, and cell culture systems that include CD133+/GlyAneg/CD45neg stem cells.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Inventors: Janina Ratajczak, Ewa K. Zuba-Surma, Mariusz Z. Ratajczak